COMMUNIQUÉS West-GlobeNewswire

Communiqué de presse : Cenrifki de Sanofi (tolebrutinib) recommandé par le Comité des médicaments à usage humain (CMUH) pour être approuvé par l’UE pour le traitement de la sclérose en plaques secondairement progressive sans poussées
24/04/2026
Cenrifki de Sanofi (tolebrutinib) recommandé par le Comité des médicaments à usage humain (CMUH) pour être approuvé par l’UE pour le traitement de la sclérose en plaques secondairement progressive sans poussées [...]
30 Years of Smiles: St. Augustine’s Premier Cosmetic Dentist Marks a Career Built on Artistry
24/04/2026
Dr. Atosa Khan celebrates three decades of dental excellence and 20 years of independent practice at one of Northeast Florida’s most distinguished dental offices ST. AUGUSTINE, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- [...]
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
24/04/2026
PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results on Friday, May 8, [...]
Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses
24/04/2026
Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses Recommendation based on the HERCULES phase 3 study which demonstrated that [...]
Treace to Report First Quarter 2026 Financial Results on May 8, 2026
24/04/2026
PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Amphista Therapeutics announces presentation of new preclinical data from its SMARCA2 and TEAD Targeted Glue™ degrader programs at AACR 2026, and publication of the first data on its TEAD program
24/04/2026
Cambridge, UK, 24 th April 2026 - Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces the presentation of new [...]
Free Carotenoid Eye Screenings Offered to Seacoast Residents Near Portsmouth, NH
24/04/2026
Fox Run Eye Care launches free carotenoid screenings for Seacoast families — and brings 25 years of patient-first optometry to a stunning new vision center in Greenland, NH GREENLAND, N.H., April 24, 2026 (GLOBE [...]
Dogecoin Cash, Inc. Highlights Telehealth Platform Strategy Following Federal Actions Relating to Marijuana Reclassification
24/04/2026
Majority-owned PrestoDoctor platform operates within state-regulated medical cannabis frameworks as federal classification evolves Mesquite, NV, April 24, 2026 (GLOBE NEWSWIRE) -- Mesquite, Nevada - Dogecoin Cash, Inc [...]
Senseonics Announces European Launch of Eversense® 365, The World’s First and Only One Year CGM System
24/04/2026
The next-generation CGM is now available in Sweden, with launches expected in Germany, Spain and Italy during the coming weeks as part of a phased roll out Eversense 365 doubles sensor lifespan from the previously [...]
Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)
24/04/2026
If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two years and older, teens and adults with SMA in the European Union Itvisma demonstrated [...]
Geneva College of Longevity Science Launches the World’s First PhD in Longevity Sciences
24/04/2026
GENEVA and CONSTANȚA, Romania, April 24, 2026 (GLOBE NEWSWIRE) -- The Geneva College of Longevity Science (GCLS) today announced the launch of the world’s first PhD in Medicine with a specialization in Longevity [...]
Levicept to Present Data from Phase II study of LEVI-04 at OARSI 2026 World Congress on Osteoarthritis
24/04/2026
SANDWICH, United Kingdom, April 24, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), will today present positive [...]
Amphista Therapeutics announces presentation of new preclinical data from its SMARCA2 and TEAD Targeted Glue™ degrader programs at AACR 2026, and publication of the first data on its TEAD program
24/04/2026
Cambridge, UK, 24 th April 2026 - Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces the presentation of new [...]
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
24/04/2026
Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded and public sector [...]
Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants
24/04/2026
Coartem® (artemether-lumefantrine) Baby is the first and only malaria treatment for newborns and young infants, closing long-standing treatment gap WHO prequalification key milestone for donor-funded and public sector [...]
CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
24/04/2026
“Totality of evidence” approach to evaluate SCENESSE® EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo study EMA emphasised its “totality of evidence” approach central [...]
Les 250 meilleurs spécialistes du cancer se réunissent en Belgique pour repousser les frontières de la protonthérapie
24/04/2026
IBA réunit les experts les plus renommés en protonthérapie venant des institutions de soins oncologiques les plus prestigieuses. Louvain-la-Neuve, Belgique, le 24 avril 2026 – IBA (Ion Beam Applications S.A., EURONEXT [...]
Vistin Pharma ASA: First quarter 2026 financial results
24/04/2026
Vistin Pharma ASA: First quarter 2026 financial results Oslo, Norway, 24 th of April 2026 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2026. First quarter revenue of MNOK 112 [...]
The top 250 cancer specialists converge in Belgium to push the frontiers of proton therapy
24/04/2026
IBA gathers the most knowledgeable proton therapy experts coming from the most prestigious cancer care institutions. Louvain-La-Neuve, Belgium, April 24, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world [...]

Pages